These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25710739)

  • 1. Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents.
    Wang NY; Xu Y; Zuo WQ; Xiao KJ; Liu L; Zeng XX; You XY; Zhang LD; Gao C; Liu ZH; Ye TH; Xia Y; Xiong Y; Song XJ; Lei Q; Peng CT; Tang H; Yang SY; Wei YQ; Yu LT
    J Med Chem; 2015 Mar; 58(6):2764-78. PubMed ID: 25710739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.
    Zhai PB; Qing J; Li B; Zhang LQ; Ma L; Chen L
    Acta Pharmacol Sin; 2018 Nov; 39(11):1746-1752. PubMed ID: 29930277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.
    Zhang N; Turpoff A; Zhang X; Huang S; Liu Y; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Pichardo J; Colacino J; Lahser F; Ingravallo P; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2016 Jan; 26(2):594-601. PubMed ID: 26652483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B.
    Cho NJ; Dvory-Sobol H; Lee C; Cho SJ; Bryson P; Masek M; Elazar M; Frank CW; Glenn JS
    Sci Transl Med; 2010 Jan; 2(15):15ra6. PubMed ID: 20371471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
    Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-acting and host-targeting HCV inhibitors: current and future directions.
    Chatel-Chaix L; Germain MA; Götte M; Lamarre D
    Curr Opin Virol; 2012 Oct; 2(5):588-98. PubMed ID: 22959589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein.
    Gu Z; Graci JD; Lahser FC; Breslin JJ; Jung SP; Crona JH; McMonagle P; Xia E; Liu S; Karp G; Zhu J; Huang S; Nomeir A; Weetall M; Almstead NG; Peltz SW; Tong X; Ralston R; Colacino JM
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3250-61. PubMed ID: 23629699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
    Rajyaguru S; Yang H; Martin R; Miller MD; Mo H
    Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B.
    Rai R; Deval J
    Antiviral Res; 2011 May; 90(2):93-101. PubMed ID: 21295075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.
    Zhang X; Zhang N; Chen G; Turpoff A; Ren H; Takasugi J; Morrill C; Zhu J; Li C; Lennox W; Paget S; Liu Y; Almstead N; Njoroge FG; Gu Z; Komatsu T; Clausen V; Espiritu C; Graci J; Colacino J; Lahser F; Risher N; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3947-53. PubMed ID: 23683597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
    Pouliot JJ; Thomson M; Xie M; Horton J; Johnson J; Krull D; Mathis A; Morikawa Y; Parks D; Peterson R; Shimada T; Thomas E; Vamathevan J; Van Horn S; Xiong Z; Hamatake R; Peat AJ
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6539-50. PubMed ID: 26259798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
    Gao M
    Curr Opin Virol; 2013 Oct; 3(5):514-20. PubMed ID: 23896281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha.
    Xu J; Liu S; Xu Y; Tien P; Gao G
    Virus Res; 2009 Apr; 141(1):55-62. PubMed ID: 19185598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of fluorobenzimidazole HCV NS5A inhibitors.
    Randolph JT; Flentge CA; Donner P; Rockway TW; Patel SV; Nelson L; Hutchinson DK; Mondal R; Mistry N; Reisch T; Dekhtyar T; Krishnan P; Pilot-Matias T; Stolarik DF; Beno DWA; Wagner R; Maring C; Kati WM
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5462-5467. PubMed ID: 27780635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor.
    Lin HM; Wang JC; Hu HS; Wu PS; Yang CC; Wu CP; Pu SY; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yeh TK; Yueh A
    Antimicrob Agents Chemother; 2012 Jan; 56(1):44-53. PubMed ID: 22006008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein.
    Tai VW; Garrido D; Price DJ; Maynard A; Pouliot JJ; Xiong Z; Seal JW; Creech KL; Kryn LH; Baughman TM; Peat AJ
    Bioorg Med Chem Lett; 2014 May; 24(10):2288-94. PubMed ID: 24731273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Structure-Resistance Relationship Study of New Thieno[2,3-
    Xiao KJ; Zuo WQ; Xu Y; Tao X; Yu LT; Wang NY
    Pharmazie; 2019 Jun; 74(6):321-325. PubMed ID: 31138367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.